KR20240110584A - 신규한 오리스타틴 유사체 및 이의 면역접합체 - Google Patents

신규한 오리스타틴 유사체 및 이의 면역접합체 Download PDF

Info

Publication number
KR20240110584A
KR20240110584A KR1020247017701A KR20247017701A KR20240110584A KR 20240110584 A KR20240110584 A KR 20240110584A KR 1020247017701 A KR1020247017701 A KR 1020247017701A KR 20247017701 A KR20247017701 A KR 20247017701A KR 20240110584 A KR20240110584 A KR 20240110584A
Authority
KR
South Korea
Prior art keywords
compound
immunoconjugate
methyl
int
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247017701A
Other languages
English (en)
Korean (ko)
Inventor
리차드 후이 리
이동준
Original Assignee
애드센트릭스 테라퓨틱스 잉크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애드센트릭스 테라퓨틱스 잉크. filed Critical 애드센트릭스 테라퓨틱스 잉크.
Publication of KR20240110584A publication Critical patent/KR20240110584A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020247017701A 2021-11-03 2022-11-02 신규한 오리스타틴 유사체 및 이의 면역접합체 Pending KR20240110584A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275177P 2021-11-03 2021-11-03
US63/275,177 2021-11-03
US202163295476P 2021-12-30 2021-12-30
US63/295,476 2021-12-30
PCT/US2022/048735 WO2023081230A1 (en) 2021-11-03 2022-11-02 Novel auristatin analogs and immunoconjugates thereof

Publications (1)

Publication Number Publication Date
KR20240110584A true KR20240110584A (ko) 2024-07-15

Family

ID=86241915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247017701A Pending KR20240110584A (ko) 2021-11-03 2022-11-02 신규한 오리스타틴 유사체 및 이의 면역접합체

Country Status (9)

Country Link
EP (1) EP4426714A4 (https=)
JP (1) JP2024540402A (https=)
KR (1) KR20240110584A (https=)
AU (1) AU2022380491A1 (https=)
CA (1) CA3236944A1 (https=)
IL (1) IL312533A (https=)
MX (1) MX2024005342A (https=)
TW (1) TW202334176A (https=)
WO (1) WO2023081230A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067221A1 (zh) * 2023-09-26 2025-04-03 上海齐鲁制药研究中心有限公司 奥瑞他汀衍生物及其抗体药物偶联物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478912B1 (en) * 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
WO2015017552A1 (en) * 2013-08-01 2015-02-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to cd37 proteins
CA3205824A1 (en) * 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof

Also Published As

Publication number Publication date
CA3236944A1 (en) 2023-05-11
EP4426714A1 (en) 2024-09-11
AU2022380491A1 (en) 2024-05-30
TW202334176A (zh) 2023-09-01
MX2024005342A (es) 2024-09-27
IL312533A (en) 2024-07-01
WO2023081230A1 (en) 2023-05-11
EP4426714A4 (en) 2025-10-08
JP2024540402A (ja) 2024-10-31

Similar Documents

Publication Publication Date Title
CA2852860C (en) Cytotoxic peptides and antibody drug conjugates thereof
CN121843944A (zh) 大环化合物及其抗体-药物偶联物
JP2023113699A (ja) ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物
CN105451773A (zh) 细胞增殖抑制剂及其缀合物
TWI712605B (zh) 含有cti藥效基團之雙功能性細胞毒性劑
CN111386275B (zh) 高活性sting蛋白激动剂
JP2018123122A (ja) カリケアマイシン誘導体およびその抗体薬物コンジュゲート
WO2024059236A1 (en) Novel camptothecin analogs and immunoconjugates thereof
CN119907693A (zh) Msln抗体药物偶联物
KR20260038273A (ko) 링커-약물 분자 및 항체 약물 접합체, 이의 제조 방법 및 용도
TW202400266A (zh) 配體藥物偶聯物及其應用
KR20240110584A (ko) 신규한 오리스타틴 유사체 및 이의 면역접합체
CN121574085A (zh) 缀合物及其用途
CA3241878A1 (en) Novel auristatin analogs and immunoconjugates thereof
HK40115429A (zh) 新型澳瑞他汀类似物及其免疫偶联物
CN118541378A (zh) 新型澳瑞他汀类似物及其免疫偶联物
CN107660208B (zh) 包含cti药效团的双功能细胞毒性剂
WO2025176733A1 (en) Antibody-drug conjugates involving small molecule atr/chk1 inhibitors
HK40117241A (zh) 新型澳瑞他汀类似物及其免疫偶联物
WO2026065268A1 (en) Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same
HK1204273B (en) Cytotoxic peptides and antibody drug conjugates thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000